Table 5.
Source | Cell Line ID | Cell Line Description | All Enhancers |
Strongest Enhancers |
||||
---|---|---|---|---|---|---|---|---|
Observed | Expected | P Value | Observed | Expected | P Value | |||
ENCODE | NHLF | Lung fibroblasts | 25 | 10.8 | 8.9 × 10−5 | 17 | 4.1 | 1.0 × 10−6 |
Roadmap | ADI.NUC | Adipose nuclei | 25 | 13.4 | 2.1 × 10−3 | 19 | 6.4 | 2.6 × 10−5 |
ADI.MSC | Adipose-derived mesenchymal stem cell cultured cells | 41 | 17.4 | <1 × 10−6 | 19 | 7 | 9.0 × 10−5 | |
LNG.FE | Fetal lung | 29 | 11 | 2.0 × 10−6 | 12 | 3.3 | 1.5 × 10−4 | |
IMR90 | IMR90 cell line | 25 | 13.1 | 1.5 × 10−3 | 16 | 7 | 2.0 × 10−3 |
Definition of abbreviations: GWAS = genome-wide association studies; LHE = local histogram-based emphysema; SNP = single-nucleotide polymorphism.
Cell lines with enrichment P values for all enhancer and strong enhancer less than 0.005 considering all SNPs associated with the Panlobular emphysema pattern and P less than 5 × 10−6.
All enhancers: enrichment measures calculated for all chromosome segmentation states associated with enhancer activity.
Strongest enhancers: enrichment measures calculated only for those chromosome segmentation states annotated as strong enhancers.
P value from binomial test comparing the observed count of GWAS SNP-enhancer overlap to the expected count derived from all SNPs in 1,000 Genomes pilot phase.